JLE

Hématologie

MENU

How to optimize the evaluation of the therapeutic response in patients with diffuse large B cell lymphoma on the first line Volume 27, supplement 1, Mars 2021

Figures


  • Figure 1

  • Figure 2

Tables

Author
Département d’hématologie clinique, Inserm U1245, centre Henri Becquerel, Rouen
* Tirés à part

Optimising the evaluation of the therapeutic response is a major challenge in the management of diffuse large B-cell lymphomas. The measurement of circulating tumour DNA (ctDNA) and the metabolic response by PET are the two pillars. These non-invasive techniques, assessing molecular and metabolic residual disease (MRD) can be combined and repeated at key times in the therapeutic phases, mainly after 2 and 4 cycles of immunochemotherapy, during the first line of treatment. An adaptive prognostic model combining on the one hand the basic characteristics (IPI) and on the other hand the MRD status (metabolic and molecular) seems relevant. However, it requires standardization of response criteria and validation of its usefulness in phase III trials.